Perspective Therapeutics’ (CATX) Outperform Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research report released on Tuesday,RTT News reports. Wedbush currently has a $11.00 price target on the stock. Wedbush also issued estimates for Perspective Therapeutics’ Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.33) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.59) EPS, FY2027 earnings at ($1.69) EPS and FY2028 earnings at ($1.27) EPS.

A number of other research firms have also recently commented on CATX. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Friday, October 3rd. BTIG Research started coverage on shares of Perspective Therapeutics in a research note on Friday, October 10th. They set a “buy” rating and a $14.00 price target on the stock. Four research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $11.89.

Perspective Therapeutics Trading Down 2.4%

Shares of NYSEAMERICAN CATX opened at $2.07 on Tuesday. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.06. The business has a 50-day moving average of $3.27 and a 200-day moving average of $3.31.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its earnings results on Monday, November 10th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.21 million. Perspective Therapeutics had a negative net margin of 7,688.50% and a negative return on equity of 33.37%. As a group, equities analysts anticipate that Perspective Therapeutics will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its stake in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Perspective Therapeutics during the third quarter valued at $46,000. Ground Swell Capital LLC bought a new position in shares of Perspective Therapeutics during the second quarter worth about $56,000. Los Angeles Capital Management LLC bought a new position in shares of Perspective Therapeutics during the second quarter worth about $61,000. Finally, MetLife Investment Management LLC increased its holdings in shares of Perspective Therapeutics by 40.9% in the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock worth $67,000 after acquiring an additional 9,082 shares during the period. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.